StockNews.AI
DTIL
StockNews.AI
151 days

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

1. Precision BioSciences (DTIL) will report Q4 and FY 2024 results on March 26, 2025. 2. The update may reveal insights on its ARCUS® gene editing platform progress.

2m saved
Insight
Article

FAQ

Why Neutral?

The announcement is routine; significant impacts depend on actual results published.

How important is it?

Upcoming financial results are critical for investors; outcomes may influence future stock trends.

Why Long Term?

The implications of financial results will unfold as long-term developments emerge.

Related Companies

CRISEDITNTLA
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that it will publish financial results for the fourth quarter and fiscal year 2024 and provide a business update on March 26, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical.

Related News